

Review

Open Access

What is the origin of pancreatic adenocarcinoma?

Parviz M Pour*^{1,2}, Krishan K Pandey³ and Surinder K Batra³

Address: ¹The Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198 USA, ²Department of Pathology and Microbiology University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198, USA and ³Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198, USA

Email: Parviz M Pour* - ppour@unmc.edu; Krishan K Pandey - kpandey@unmc.edu; Surinder K Batra - sbatra@unmc.edu

* Corresponding author

Published: 22 January 2003

Received: 21 December 2002

Molecular Cancer 2003, 2:13

Accepted: 22 January 2003

This article is available from: <http://www.molecular-cancer.com/content/2/1/13>

© 2003 Pour et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

The concept of pancreatic cancer origin is controversial. Acinar, ductal or islet cells have been hypothesized as the cell of origin. The pros and cons of each of these hypotheses are discussed. Based on the world literature and recent observations, pancreatic cells seem to have potential for phenotypical transdifferentiation, i.e. ductal-islet, ductal-acinar, acinar-ductal, acinar-islet, islet-acinar and islet-ductal cells. Although the possibility is discussed that cancer may arise from either islet, ductal or acinar cells, the circumstances favoring the islet cells as the tumor cell origin include their greater transdifferentiation potency into both pancreatic and extrapancreatic cells, the presence of a variety of carcinogen-metabolizing enzymes, some of which are present exclusively in islet cells and the growth factor-rich environment of islets.

Introduction

The complex cellular structure of the pancreas composed of various exocrine and endocrine cells hampers a clear understanding of the origin of pancreatic ductal-type adenocarcinoma. During the embryonic development of the pancreas all exocrine and endocrine cells are derived from the common precursor cells, the stem cells. It is believed that these stem cells are retained in the adult pancreas and are the foundation for cell renewal and tumors; however, this claim has remained illusive. Recent studies pointing to the enormous plasticity of each type of pancreatic cell in changing their phenotype from one type to another (i.e., transdifferentiation) makes the identification of tumor cell origin more complex. The islet-ductal, acinar-ductal, ductal-islet cell transdifferentiation in purified cell populations [1–6] and *in vivo* [7–10] has been observed. Consequently, all pancreatic cells could be considered as a potential facultative stem cell.

There is accumulating evidence that most pancreatic tumors originate from within islets by islet cell transdifferentiation and that pancreatic islet cells play a significant role in the neoplastic process. There are also observations that favor that the ductal cells are the source of cancer cells. To better understand the neoplastic process in the pancreas, some anatomic-physiological aspects of the tissue should be considered.

Review

Interaction between the exocrine and endocrine cells

It is estimated that the exocrine cells contribute to over 95% (acinar cells 85%, ductal cells 10%) of the volume of the pancreas, whereas the endocrine cells are believed to occupy only 1–2% of the pancreatic volume in adults. Clearly, this estimation is misleading as it does not consider the number of individual cell types. When the size of the cells is disregarded, the figures would be significantly different. The circular three-dimensional shape of the islets composed of relatively small, closely packed cells

causes underestimation of their numbers in histological sections. Considering the diffuse distribution of the islets, accounting for about one islet per 1.1 mm² of the tissue [11], and the presence of a large number of a single or small group of islet cells scattered throughout the pancreas and within the ductal epithelium it appears that there are as many islet cells as acinar cells. The same applies to ductal cells, as the calculation does not consider the often-invisible centroacinar cells that are the components of ducts. According to our observation, within an acinus there are as many centroacinar cells as acinar cells. In our view, centroacinar cells are as multipotential as islet cells and can give rise to islet cells, acinar cells and tumor cells [12].

The tight functional and physical interaction between the endocrine and exocrine cells have been well established but not sufficiently investigated. The necessary cooperation between the endocrine and exocrine cells well explains the plasticity of the pancreas to adjust to the internal demands and external stimuli. Hence, each type of pancreatic cells has the ability to provide a function that is dictated by the physiological demand in an organized fashion. Islet cells seem to be the frontrunner of the organization system.

Islet cells, the gatekeeper of the pancreas

The diffuse distribution of islet cells throughout the pancreas either in the form of aggregate (islet) and single or small group of islets indicate their important function. They seem to control the flow of pancreatic exocrine and exocrine function as reflected by their unique ability for transformation to every pancreatic and some extrapancreatic cell type [1–8]. The controlling effect of islet cells on the exocrine tissue is also highlighted by the presence of endocrine cells within the normal, hyperplastic and malignant ductal epithelium, in both humans and animals [13–17]. Another extremely important function of the islet cells, not similarly shared by other pancreatic cells, is the defensive strategy provided by drug-metabolizing enzymes. Among the two major groups of drug-metabolizing enzymes in mammals, cytochrome P450 isozymes (CYP) and glutathione S-transferases (GST) [18–22], which are known to be involved in the metabolism of a variety of toxins and carcinogens, were found to be expressed primarily or exclusively in the islet cells of every species that we have investigated, including humans, monkeys, pigs, dogs, guinea pigs, rabbits, rats, hamsters and mouse [19]. This implies a greater involvement of islet cells in the metabolism of xenobiotics within the pancreas. Strikingly, in humans, four of the CYP isozymes were expressed exclusively in the PP cells, and two isozymes were expressed in a higher concentration in the PP cells than in the other islet cells [22]. Considering the anatomical blood supply of the pancreas, the primary pres-

ence of the xenobiotic enzymes in the islets is self explanatory, as in humans and other mammalian species, part of the arterial blood passes through the islets before nourishing the exocrine pancreas [23–27].

Evidence for the derivation of tumors from islet cells

Experimental data

The following observations support the unequivocal role of β -cells in transdifferentiation and, thus the carcinogenesis process: 1) Experimentally, the first histological alterations are the appearance of intrainsular ductular structures showing different stages of progression from normal to malignant pattern. These lesions are initially confined within the islet boundary and are sharply demarcated from the surrounding tissue (Fig. 1a,1b,1c). 2) The pretreatment of hamsters with streptozotocin, which selectively destroys β -cells, inhibits the pancreatic tumorigenesis [28]; 3) Genetically diabetic hamsters with depleted β -cells are resistant to the pancreatic carcinogenic effect of N-nitrosobis(2-oxopropyl)amine (BOP), whereas the pancreas of a non-diabetic strain with intact β -cells is not [29]; 4) Stimulation of β -cell neogenesis (nesidioblastosis) enhances pancreatic carcinogenicity of BOP [30]; 5) Transplantation of homologous islets into the submandibular gland (a non-target tissue of BOP) of hamsters and the subsequent BOP treatment of the recipient hamsters results in the development of ductal-type adenocarcinomas in the areas of transplanted islets [31,32]. Histological findings point to the development of malignant glands in the center of islets, the exclusive position of β -cells in hamsters; 6) Malignant transformation of freshly isolated hamster pancreatic islets by BOP *in vitro* [33]. Although the treatment of cultured hamster pancreatic ductal cells also led to the formation of ductal adenocarcinomas [34] these tumors, contrary to those derived from islet cells [33], did not show the mutation of the c-K-ras oncogene [35], the most common genetic abnormality in human pancreatic adenocarcinomas [36,37]. Additionally, only the cultured islets cells treated with BOP showed an inactivation of the p16 (INK4a) gene (homozygous deletion) [38], which is found in 90–100% of human pancreatic adenocarcinomas [39]; 7) BOP-treatment of freshly isolated islets containing β -cells, but not those which were depleted of β -cells, resulted in malignant transformation (unpublished); 8) Isolated human islets but not human ductal cells treated with BOP could be grown in serum-free, growth factor-free medium and showed a mutation of c-Ki-ras (unpublished). In neither of the *in vivo* and *in vitro* studies could we identify cells which could be regarded as stem cells although more than 50 human and hamster islets were subjected to electron microscopical examination [1–3]. Considering the rarity of stem cells among the mature cells, however, (about 1 in 10,000 in bone marrow [40]), we could have missed the identification of these cells.




Figure 1

Formation of malignant ductular structures within hamster's islets. **a)** The lesions is confined to the islets and is sharply demarcated from the surrounding tissue by a layer of fibrosis and inflammatory cells invaded by cancer. H&E $\times 30$. **b)** Similar lesions showing irregularly shaped malignant glands replacing the islet. H&E $\times 30$. **c)** In this lesions most part of islet is replaced by malignant gland and sclerosis. Note the sharp delineation of the lesions. Local cancer invasion is seen in the lower portion. H&E $\times 30$. **d)** An atrophic islet in a patients with chronic pancreatitis. A ductular structure (*arrow*) is composed of light eosinophilic and clear cells intermingled with islet cells. H&E $\times 120$. **e)** Another atrophic human islet far remote of a cancer. A dysplastic ductular structure (*arrow*) in the islet without any signs of depression in the surrounding islet cells. H&E $\times 120$. **f)** An islet in the vicinity of a well-differentiated adenocarcinoma containing large atypical cells (*arrows*) intermingled with intact islet cells. H&E $\times 72$. **g)** A human islet cell in a patient with pancreatic adenocarcinoma loaded with material immunoreactive with anti-MUC-1 antibody (fine granules). Although in these islets the immunoreactivity with anti-insulin has diminished, some granules show reactivity with anti-insulin (*arrows*). $\times 104,000$, **h)** Normal human islet. One endocrine cell shows a typical cilia identical to those present in ductal-ductular cells. $\times 7,200$. **i)** Fine structure of a well-differentiated adenocarcinoma, some cells of which show a few regular or rudimentary granules of endocrine type (*arrow*). $\times 7,200$.

Clinical data

Intra-islet ductular formation and their malignant counterparts have also been observed in the human pancreas [17,41–43]. Around 70% of pancreatic cancer patients, who clinically have an altered glucose tolerance, islet cells lose their reactivity to anti-insulin and express ductal cell markers, including carbohydrate antigen CA-19-9, DU-PAN-2 and Tag-72, and develop intra-islet ductular structures (Fig. 1d,1e) that express the same antigens [42,43]. Moreover, the occurrence of the same antigen in islet cells and in intra-islet ductular cells within the same islet [42–44] indicates a causal relationship between the altered islet cells and intra-islet ductular cells. In some islets, single or a group of large atypical cells, suggesting malignant cells (Fig. 1f) can be seen as was also found in our previous studies [17]. Our electron microscopic examinations have shown that the normal-appearing islet cells within the altered islets contain Muc1 (Fig. 1g), the backbone of these carbohydrate antigens. Moreover single cilia, (Fig. 1h), which is a specialized structure of ductal/ductular cells [45], can be found in islet cells. This structure along with other changes observed during transdifferentiation, indicate that islet cells have the inherent ability to make phenotypical changes and that the genes involved in the differentiation of different pancreatic cells are closely related. This process is also highlighted by the presence of endocrine-like granules in some cancer cells (Fig. 1i.), which can express neuroendocrine cell markers, including NSE, neuronal adhesion molecule [46] and β -tubulin (Fig. 2a). The presence of islet cells within the malignant epithelium, sometimes exceeding the number of tumor cells [16] is a clear indication that tumor cells are derived from transdifferentiated islet cells, which seem to present facultative precursor cells.

Pathophysiological consideration

Islet cells are the major pancreatic cells that are equipped with a variety of drug-metabolizing enzymes. Based on the aforementioned insulo-portal blood vessels, xenobiotic first reaches the islets, where it is metabolized to either a non-toxic or a proximate carcinogen. The latter substances generally react in millisecond with the target DNA to form adducts required for the neoplastic process, which triggers the transformation of the affected islet cells to undifferentiated, intra-islet duct-like cells. One can argue that because of the lack of or low concentration of the enzymes, the ductal and acinar cells are exposed to the carcinogen in a much lesser degree and the damaged DNA are repaired quickly. As will be discussed below, the presence of only a few cells containing drug-metabolizing enzymes within the ductal epithelium, from which we believe that ductal cell alteration occurs could explain the reason for the much later appearance of ductal alteration. In the islet cells, however, the extent of DNA damage may exceed the repair capability and the presence of a massive

amount of growth factors within the islets could trigger the promotion of the neoplastic process. This may explain the reason for the initial development of the lesions within the islets. In this context, the expression of CYP2E1 by PP cells, which are frequently present in a large number within the ductal epithelium [22], is noteworthy, because this enzyme is involved in the metabolism of carcinogenic nitrosamines, some of which are present in tobacco smoke [47,48], and suggested to present pancreatic carcinogens. Whether or not this peculiar distribution of carcinogen-metabolizing enzymes in PP cells is the reason for the frequent development of pancreatic cancer in the head of the pancreas [20], is a hypothetical question.

Evidence for the derivation of tumors from ductal cells

The ductal cell structure of the majority of pancreatic tumors and the ability of ductal cells to proliferate are the overwhelming reasons to suggest that ductal cells are the origin of pancreatic adenocarcinomas. The expression of ductal markers, in cancer cells goes along with this possibility. Indeed, some types of cancer, the intra-ductal tumors, seem to arise from ductal cells and remain within the ductal boundary for a while before invasion. The apparent ability of ductal cells to differentiate into other cell types, including squamous, mucinous and pyloric cells further supports the ability of ductal cells to undergo malignant transformation.

One of the landmark studies suggesting histological evidence for ductal cell origin of pancreatic cancer came from a study of Cubilla and Fitzgerald [49], who studied 227 patients and observed that the incidence of ductal hyperplasias in patients with pancreatic cancer was much greater than in those without cancer. The presence of similar spatial distribution of lesions in tumors was consistent with the hypothesis that such lesions might represent incipient pancreatic adenocarcinoma. These findings were later confirmed by other investigators [50,51]. The only problem with these studies was that they were done at one particular stage and hence these findings were arguable in the sense that whether these pancreatic duct lesions represented the intra-ductal extension of an invasive cancer or they themselves are a true precursor to invasive cancer. In these morphological studies proposing lesions to be the precursor of infiltrating cancer, there was no direct evidence apart from the morphological unusual growth that these lesions actually progressed to invasive ductal cancer.

The suggestion of ductal cells as a precursor of cancer cells is derived mostly from pathomorphological studies. In one study involving two patients who had atypical papillary duct lesions, it was observed that they developed invasive pancreatic adenocarcinoma a couple of years later [52]. In another study, [53] three patients developed infiltrating ductal pancreatic adenocarcinoma one and half to




Figure 2

a) Numerous Helle Zelle (light cells) in hyperplastic ductal epithelium corresponding to PanIN2 (arrows). The cells are small with light cytoplasm and hyperchromatic round or oval nuclei. Some cells seem to have two nuclei (the second and third arrows from left). H&E $\times 120$. **b)** A lesions comparable to PanIN1 to PanIN3 showing clear cells with a small round nuclei surrounded by a halo (arrow). One of the clear cells (arrowhead) presents two nuclei (post mitotic division?). H&E $\times 120$. **c)** Electron microscopic findings of a similar lesion. Note several clear cells with one or two nuclei. The cells are poor on cell organelles and lay between the basal membran and tumor cells. $\times 7,200$. **d)** Hyperplastic ductules in an elderly man. Several clear cells are seen within the epithelium. A small group of these cells have interrupted the continuity of the epithelium (bottom arrow) or extended into the stroma (top arrow). H&E $\times 120$. **e)** Many of the clear cells that can form a circular layer all along the duct, are immunoreactive with antibodies against islet hormones, especially to anti-glucagon and -chromogranin A and against drug-metabolizing CYP450 enzymes. ABC method, Anti-glucagon, $\times 120$. **f)** A large number of endocrine cells reactive with anti-chromogranin A antibody in a malignant gland. ABC method, $\times 120$. **g)** A large malignant gland exhibiting papillary infolding of the epithelium. A remarkably large number of overlapping endocrine cells are present in the basal layer of the malignant epithelium. ABC, combination of anti-insulin and anti-glucagon, 120.

ten years later after the histological confirmation of atypical papillary ductal lesions in their pancreata. These findings involving morphological observations suggest that pancreatic ductal hyperplasia is a precursor to pancreatic cancer. Unlike in breast, skin, colon cervix or prostate, which are accessible for non-invasive biopsies, the recognition of an early form of cancer is difficult. The location of the pancreas, deep in the abdomen and the silent course of pancreatic cancer makes this approach difficult. Due to this reason, the described progression of pancreatic ductal lesions to invasive pancreatic cancer is illusive at best.

On the basis of morphological, clinical, and genetic observations, a progression model for pancreatic ductal adenocarcinoma has been proposed. According to the new classification of ductal lesions as pancreatic intraductal neoplasia (PanIN), progression of hyperplasia to malignancy through a series of architectural and cytological changes have been described [49]. Based on the degree of cytological and architectural atypia the lesions have been subclassified into PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3 [54,55]. In a global sense, PanIN-1A stage epithelial lesions present tall columnar mucin-containing cells showing slight or no atypia; PanIN-1B designates epithelial lesions that have a papillary, micropapillary, or basally pseudostratified architecture but are otherwise identical to PanIN-1A. PanIN-2 lesions show moderate atypia including loss of polarity, nuclear crowding, nuclear enlargement, pseudo-stratification, and nuclear hyperchromatism. PanIN-3 epithelial lesions are usually papillary or micropapillary with severe atypia.

It is, however, unclear whether these lesions in pancreatic cancer patients were merely the outgrowth of an invasive cancer, as shown experimentally [56] and in humans [57], rather than the precursor themselves. If, as the morphological observations suggest, the duct lesions are *de novo* and indeed the precursors to invasive pancreatic cancer, then the lesions should be clonal and harbor some but not necessarily all of the mutations and genetic alterations found in associated infiltrating carcinomas. Moreover, the incidence of these genetic alterations should increase with severity of cytological and architectural atypia in duct lesions. Studies, however, show evidence that such lesions are polyclonal and show heterogeneity in genetic alterations [58]. The presence of a number of genetic alterations found in pancreatic cancer and in these lesions does not prove a causal relationship, because, as described above, there is no evidence that these ductal lesions are the extension of already existing tumors, which are known to be transferred by pancreatic juice and seed in a location remote from the primary cancer [56,57]. The genes which have been found to be altered include *K-ras*, *p16*, *HER2/Neu*, *MUC4*, *DPC4* and *BRCA2*. Furthermore, the inci-

dence of these genetic changes increases as the degree of cytological and architectural atypia in the duct lesions increases.

Mutations in oncogene *K-ras* and overexpression of *HER2* are supposed to be the early events in the progression of ductal carcinoma as they have also been reported in ductal lesions with minimal atypia. *K-ras* has been found to be inactivated in about 95% of pancreatic cancer patients [59]. *HER2/Neu* is reportedly not overexpressed in normal ductal epithelium of the pancreas but is said to be overexpressed in almost all duct lesions having significant cytological and architectural atypia [60]. Our own investigation, however, demonstrated that *HER2/Neu* is overexpressed in pancreatic ductal cells in chronic pancreatitis and its expression in cancer cells was strikingly heterogeneous and weak [61]. Moreover, the antibodies used had a greater reactivity with islet and neuroendocrine cells than with cancer cells [58]. Inactivation of tumor suppressor gene *CDKN2A (p16)* cyclin dependent kinase inhibitor occurs later and the loss of expression of the *p16* gene could be correlated with the severity of cytological and architectural atypia [62]. Inactivation of *CDKN2A*, by mutation, deletion or promoter hypermethylation also is a common event in pancreatic cancer and occurs in about 80–95% of invasive pancreatic adenocarcinomas [63]. A number of studies have identified common mutational profiles in simultaneous lesions indicating the relationship between PanINs and the pathogenesis of pancreatic adenocarcinomas. Although common mutation patterns in PanIN and associated adenocarcinoma have been observed for *K-ras* and *p16* [64], as stated earlier, the derivation of ductal cell abnormality from original ductal cells or cancer cells is not clear. It was suggested that alterations of the *p16* gene affect a subset of pancreatic intraductal lesions that contain mutations of the *K-ras* gene and that these mutations might identify high-risk precursors of the invasive malignancy. Loss of other tumor suppressor genes like *p53*, *BRCA2* and *DPC4 (Smad4)* occurs later in neoplasia development. The inactivation of *K-ras*, however, is not a marker for malignancy because the mutation can also be found in non-malignant ductal epithelium [65].

The *p53* mutations seem to occur late in PanINs, which have acquired significant features of dysplasia, reflecting the function of *p53* in preventing malignant progression. The loss of *p53* would result in aberrant genetic instability which is very much a characteristic of invasive pancreatic cancer. Mutations in *BRCA2* have been primarily associated with familial breast and ovarian cancers but it has also been observed in approximately 17% of pancreatic cancer patients having a family history [66]. Normally *BRCA2* is responsible for homologous recombination based DNA repair and thereby maintaining the genomic stability.




Figure 3

a) focal papillary proliferation of the epithelium of the main pancreatic duct of a hamster. Note the lack of continuity between the hyperplastic foci. In such lesions, generally a few or many endocrine cells are present. H&E $\times 32$. **b)** Part of a malignant epithelium in a male with pancreatic adenocarcinoma. Note the presence of insulin-positive cells (*brown in color*) at the base of papillary configuration of the epithelium. Multilabeling with several antibodies against the four islet hormones reveals a larger number of immunoreactive cells. ABC method, $\times 120$.

BRCA2 gets mutated later in the progression of dysplasia probably because DNA damaging response pathways might have to be inactivated first (*i.e.* *p53* mutation so that damages suffered could be tolerated). The *MUC4* mucin has also been shown to be one of the characteristic markers for pancreatic cancer [67]. A recent study on 71 PanIN lesions of different grades and 28 invasive carcinomas shows a steady increase in *MUC4* expression along with the increase in severity of pancreatic duct lesion [67,68]. Normal pancreatic ducts do not express *MUC4*. Increasing expression of *MUC4* with an increasing grade of PanIN supports the assumption of PanIN being a precursor for infiltrating pancreatic ductal adenocarcinoma. Our unpublished data, however, shows that *MUC4* is expressed in ductal cells of chronic pancreatitis. Whether this finding supports the unspecificity of *MUC4* for cancer or chronic pancreatitis-cancer sequence, remains to be seen.

All this information about the progression of genetic abnormality in pancreatic ductal lesions are illusive until a proof is provided that those lesions are primary alterations. Their association with pancreatic cancer casts doubt on their primary nature. If they were primary alterations and show progression, the incidence of pancreatic cancer multiplicity would be high. The opposite, however, is true.

The argument that the expression of ductal markers in ductal adenocarcinoma notwithstanding indicates the derivation of cancer cells from ductal cells is unsupported. We have shown that during the transdifferentiation process of islet cells, various markers, including markers for stem cells (nestin), ductal cells (cytokeratin 7, 19, pancytokeratin, CA 19-9, TAG-72, DU-PAN-2), mesenchymal cells (vimentin, fibronectin) and others (α -1 antiprotease) are expressed [1-3].

The genetic abnormalities also are not convincing evidence as these alterations can occur in cancer cells derived from transdifferentiated acinar or islet cells. The vital question that has remained is the cell of origin of ductal lesions. Are these lesions the result of proliferation and progression of fully-differentiated ductal cells or by metaplastic conversion of other pancreatic cell types through emigration and transdifferentiation [69]?

There are circumstances that argue against the involvement of mature ductal cells in malignancy. It is totally unclear, whether it is ductal cells *per se* or other cells within the ductal epithelium with the ability for transdifferentiation and malignancy. It has been suggested that some cells with stem cell characters reside within ductal epithelium [70,71]. In histological sections stained with hematoxylin and eosin we have identified cells, smaller than ductal

cells with "clear" cytoplasm and round oval hyperchromatic nuclei, which seems to correspond with the "Helle Zelle" (light cells) described by Feyrter [70] and Bonner-Weir [71] in the normal epithelium. A large number of hyperplastic, dysplastic and malignant epithelium, corresponding to PanIN 1–3 (Fig. 2a,2b). Some of these cells are double nucleated and perhaps represent cell division (Fig. 2c). Single clear cells can be observed within the epithelium at the level of other ductal cells or as a single cell or in a small group outside of the ductal basal membrane and in connection with the basal clear cells (Fig. 2d). These observations suggest that the clear cells have the potential to form either ductal cells (to produce hyperplastic epithelium) or endocrine cells. Many, but not all of these clear cells express endocrine cell markers and the same drug-metabolizing enzymes as islet cells. (Fig 2e). In some cases, the number of the endocrine cells nearly exceeds the number of tumor cells (Figs. 2f and 2g).

Considering the event that ductal cell hyperplasia or dysplasia initially occurs locally and expands gradually (Fig. 3a), and because within the altered epithelium various number of endocrine cells can be identified (Fig. 3b), it is reasonable to assume that ductal alterations arise from clear cells, possibly derived from transdifferentiated endocrine cells. Equally, it is possible that the clear cells are the precursor of both ductal and endocrine cells. The original source of these clear cells is also unclear. They are few in the normal duct, but plenty in hyperplastic ducts. In the latter case, their random distribution within the epithelium makes their origin from a few preexisting cells unlikely. Their derivation from mature ductal cells by transdifferentiation is equally hard to accept as mature ductal cells have a tendency to divide directly without going through an intermediate stage. Whether or not these clear cells originate from extrapancreatic cells, as described in other tissues [69] is a hypothetical possibility. Nevertheless, the ability of these cells for the proliferation and metabolism of various xenobiotics make them the primary origin of tumors.

Hence, the data on the origin of pancreatic cancer cells leaves much room for speculation. There is as yet, no definite proof for islet cells or ductal cells as cancer precursor cells, although the possibility of the involvement of islet cells is overwhelming. Future molecular biological studies during cell differentiation in the embryonic and adult tissue could help to understand this presently controversial issue.

Evidence for the derivation of tumors from acinar cells

Based on the suggested transformation of acinar cells to duct-like cells, a school of thought considers acinar cells as the tumor progenitor cells. Evidence, however, is missing. Although, in the rat model, as well as in humans,

transdifferentiation of acinar cells to duct-like structures (pseudoductules) have been reported [70]. The question whether pseudoductules develop from centroacinar cells or from acinar cells, however, has not been settled. Our studies have shown that during carcinogenesis centroacinar cells enlarge, form long cytoplasmic extensions that cover the entire surface of acinar cells, separate acinar cells from each other and from the basal membrane, hence, by necrotizing the acinar cells that replaces them [10]. We have made the same observation in human chronic pancreatitis tissue (unpublished). During this degenerative, reparative process, some centroacinar cells seem to form islet cells as endocrine cells are identified within the affected acini [12]. The suggested transdifferentiation of acinar cells to ductular cells *in vitro* [72,73] does in no way exclude the role of centroacinar cells in pseudoductular formation, as generally, centroacinar cells are tightly attached to acinar cells. Presently, however, a transformation of acinar cells to ductular cells can not be entirely ruled out with certainty. Detailed morphological and molecular biological studies are needed to settle the controversy. Nevertheless, considering the plasticity of pancreatic cells, tumor cells can derive from any pancreatic cells.

Conclusion

The overwhelming evidence points to the derivation of pancreatic cancer from transdifferentiated islet cells within islets and within the ductal epithelium. The remarkable transdifferentiation tendency of islet cells to a variety of pancreatic and extrapancreatic cells, found also in both induced and human cancers, the presence of various drug-metabolizing enzymes in all tested species make this cell the most possible primary tumor origin. The striking transdifferentiation capability of islet cells into other cell types also indicates a close functional relationship between the genes that are responsible for the differentiation toward acinar, ductal and islet cell phenotypes. The circumstances favoring the origin of cancer cells from islet cells could well be the environment rich on growth factors.

Acknowledgment

This work was supported, in part, by grants from the National Cancer Institute's SPORE Grant No. P50CA72712, the National Cancer Institute Laboratory Cancer Research Center support grant CA367127, and the American Cancer Society Special Institutional Grant.

References

1. Schmieid BM, Liu G, Matsuzaki H, Ulrich A, Hernberg S, Moyer MP, Weide L, Murphy L, Batra SK and Pour PM **Differentiation of islet cells in long-term culture.** *Pancreas* 2000, **20**:337-47
2. Schmieid BM, Ulrich A, Matsuzaki H, Ding X, Ricordi C, Weide L, Moyer MP, Batra SK, Adrian TE and Pour PM **Transdifferentiation of human islet cells in a long-term culture.** *Pancreas* 2001, **23**:157-71

3. Schmieid BM, Ulrich AB, Matsuzaki H, Ding X, Ricordi C, Moyer MP, Batra SK, Adrian TE and Pour PM **Maintenance of human islets in long term culture.** *Differentiation* 2000, **66**:173-80
4. Yuan S, Rosenberg L, Paraskevas S, Agapitos D and Duguid WP **Transdifferentiation of human islets to pancreatic ductal cells in collagen matrix culture.** *Differentiation* 1996, **61**:67-75
5. Kerr-Conte J, Pattou F, Lecomte-Houcke M, Xia Y, Boilly , Proye C and Lefebvre J **Ductal cyst formation in collagen-embedded adult B human islet preparations. A means to the reproduction of nesidioblastosis in vitro.** *Diabetes* 1996, **45**:1108-14
6. Lucas-Clerc C, Massart C, Campion JP, Launois B and Nicol M **Long-term culture of human pancreatic islets in an extracellular matrix: morphological and metabolic effects.** *Mol Cell Endocrinol* 1993, **94**:9-20
7. Pour PM and Schmieid BM **One thousand faces of Langerhans islets.** *Int J Pancreatol* 1999, **25**:181-93
8. Kloepfel G **Endokrin Pankreas und Diabetes Mellitus. Spezielle pathologische Anatomie (Edited by: Doerr W, Seifert) Berlin: Springer Verlag** 1981, 523-728
9. Alpert S, Hanahan D and Teitelman G **Hybrid insulin genes reveal a developmental lineage for pancreatic endocrine cells and imply a relationship with neurons.** *Cell* 1988, **53**:295-308
10. De Krijger RR, Aanstoot HJ, Kranenburg G, Reinhard M, Visser WJ and Bruining GJ **The midgestational human fetal pancreas contains cells coexpressing islet hormones.** *Dev Biol* 1992, **153**:368-75
11. Pour PM **Islet cells as a component of pancreatic ductal neoplasms. I. Experimental study: ductular cells, including islet cell precursors, as primary progenitor cells of tumors.** *Am J Pathol* 1978, **90**:295-316
12. Pour PM **Mechanism of pseudoductular (tubular) formation during pancreatic carcinogenesis in the hamster model.** *Am J Pathol* 1988, **130**:335-344
13. Kodoma T **A light and electron microscopic study on the pancreatic ductal system.** *Acta Pathol Jpn* 1983, **33**:297-321
14. Chen J, Baithun SI, Pollock DJ and Berry CL **Argyrophilic and hormone immunoreactive cells in normal and hyperplastic pancreatic ducts and exocrine pancreatic carcinoma.** *Virchows Arch A Pathol Anat Histopathol* 1988, **413**:399-405
15. Bendayan M **Presence of endocrine cells in pancreatic ducts.** *Pancreas* 1987, **2**:393-397
16. Pour PM, Permert J, Mogaki M, Fujii H and Kazakoff K **Endocrine aspects of exocrine cancer of the pancreas. Their patterns and suggested biological significance.** *Am J Clin Pathol* 1993, **100**:223-230
17. Pour PM and Wilson RB **Experimental tumors of the pancreas.** In: *Tumors of the pancreas (Edited by: Moossa AR) Baltimore-London, Williams and Wilkins* 1980, 37-158
18. Ulrich AB, Schmieid BM, Standop J, Schneider MB, Lawson TA, Friess H, Andren-Sandberg A, Buechler MW and Pour PM **Differences in the expression of glutathione S-transferases in normal pancreas, chronic pancreatitis, secondary chronic pancreatitis and pancreatic cancer.** *Pancreas* 2002, **24**:291-297
19. Ulrich AB, Standop J, Schmieid BM, Schneider MB, Lawson TA and Pour PM **Species Differences in the Distribution of Drug-metabolizing Enzymes in the Pancreas.** *Toxicol Pathol* 2002, **30**:247-253
20. Ulrich AB, Standop J, Schmieid BM, Schneider MB, Lawson TA and Pour PM **Expression of drug-metabolizing enzymes in the pancreas of hamster, mouse, and rat, responding differently to pancreatic carcinogenicity of BOP.** *Pancreatol* 2002, **2**:519-527
21. Standop J, Schneider MB, Ulrich A, Chauhan S, Moniaux N, Buechler MW, Batra SK and Pour PM **The pattern of xenobiotic-metabolizing enzymes in the human pancreas.** *J Toxicol Environ Health* 2002, **65**:1379-1400
22. Standop J, Ulrich AB, Schneider MB, Buechler MW and Pour MP **Differences in the expression of xenobiotic metabolizing enzyme between islets derived from the ventral and dorsal anlage of the pancreas.** *Pancreatol* 2002, **2**:510-518
23. Murakami T, Fujita T, Taguchi T, Nonaka Y and Orita K **The blood vascular bed of the human pancreas, with special reference to the insulo-acinar portal system. Scanning electron microscopy of corrosion casts.** *Arch Histol Cytol* 1992, **55**:381-95
24. Murakami T, Hitomi S, Ohtsuka A, Taguchi T and Fujita T **Pancreatic insulo-acinar portal systems in humans, rats, and some other mammals: scanning electron microscopy of vascular casts.** *Microsc Res Tech* 1997, **37**:478-88
25. Lifson N, Kramlinger KG, Mayrand RR and LE J **Blood flow to the rabbit pancreas with special reference to the islets of Langerhans.** *Gastroenterology* 1980, **79**:466-473
26. Ohtani O, Ushiki T, Kanazawa H and Fujita T **Microcirculation of the pancreas in the rat and rabbit with special reference to the insulo-acinar portal system and emissary vein of the islet.** *Arch Histol Jpn* 1986, **49**:45-60
27. Miyake T, Murakami T and Ohtsuka A **Incomplete vascular casting for a scanning electron microscope study of the microcirculatory patterns in the rat pancreas.** *Arch Histol Cytol* 1992, **55**:397-406
28. Pour PM, Kazakoff K and Carlson K **Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin.** *Cancer Res* 1990, **50**:1634-1639
29. Bell RH Jr and Pour PM **Pancreatic carcinogenicity of N-nitrosobis(2-oxopropyl)-amine in diabetic and non-diabetic Chinese hamsters.** *Cancer Lett* 1987, **34**:221-30
30. Pour PM and Kazakoff K **Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model.** *Am J Pathol* 1996, **149**:1017-25
31. Pour PM, Weide L, Liu G, Kazakoff K, Scheetz M, Tshkov I, Ikematsu Y, Fienhold MA and Sanger W **Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans.** *Am J Pathol* 1997, **150**:2167-80
32. Fienhold MA, Kazakoff K and Pour PM **The effect of streptozotocin and a high-fat diet on BOP-induced tumors in the pancreas and in the submandibular gland of hamsters bearing transplants of homologous islets.** *Cancer Lett* 1997, **117**:155-60
33. Schmieid B, Liu G, Moyer MP, Hernberg IS, Sanger W, Batra S and Pour PM **Induction of adenocarcinoma from hamster pancreatic islet cells treated with N-nitrosobis(2-oxopropyl)amine in vitro.** *Carcinogenesis* 1999, **20**:317-321
34. Ikematsu Y, Liu G, Fienhold MA, Cano M, Adrian TE, Hollingsworth MA, Williamson JE, Sanger W, Tomioka T and Pour PM **In vitro pancreatic ductal cell carcinogenesis.** *Int J Cancer* 1997, **72**:1095-103
35. Takahashi T, Moyer MP, Cano M, Wang QJ, Mountjoy CP, Sanger W, Adrian TE, Sugiura H, Katoh H and Pour PM **Differences in molecular biological, biological and growth characteristics between the immortal and malignant hamster pancreatic ductal cells.** *Carcinogenesis* 1995, **16**:931-939
36. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M **Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.** *Cell* 1988, **53**:549-54
37. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL and Bos JL **K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.** *Am J Pathol* 1993, **143**:545-54
38. Muscarella P, Knobloch TJ, Ulrich AB, Casto BC, Moniaux N, Wittel UA, Melvin VS, Pour PM, Song H, Gold B, Batra SK and Weghorst CM **Identification and sequencing of the Syrian Golden hamster (Mesocricetus auratus) p16(INK4a) and p15(INK4b) cDNAs and their homozygous gene deletion in cheek pouch and pancreatic tumor cells.** *Gene* 2001, **278**:235-243
39. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Bayliss SB, Kern SE and Herman JG **Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.** *Cancer Res* 1997, **57**:3216-3230
40. Alison MR, Poulosom R, Forbes S and Wright NA **An introduction to stem cells.** *J Pathol* 2002, **197**:419-423
41. Kimura W, Morikane K, Esaki Y, Chan WC and Pour PM **Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy.** *Cancer* 1998, **82**:1839-49
42. Pour PM, Schmieid BM, Ulrich AB, Friess H, Andren-Sandberg A and Buechler MW **Abnormal differentiation of islet cells in pancreatic cancer.** *Pancreatol* 2000, **1**:110-116
43. Schmieid BM, Ulrich AB, Matsuzaki H, Li C, Friess H, Buechler MW, Andren-Sandberg A, Adrian TE and Pour PM **Alteration of the**

- Langerhans islet in pancreatic cancer patients.** *Int J Pancreatol* 2000, **28**:187-197
44. Ogrowsky D, Fawcett J, Althoff J, Wilson R and Pour PM **Structure of the pancreas in Syrian hamsters.** *Acta Anat (Bases)* 1980, **107**:121-128
 45. Pour PM and Morohoshi T **Ductal adenocarcinoma.** In: *Atlas of Exocrine Pancreatic tumors. Morphology, Biology and Diagnosis with an International Guide for Tumor Classification* (Edited by: Pour PM, Konoshi Y, Langnecker DE, Kloepfel G) Springer Verlag, Japan 1994, 117-154
 46. Tezel E, Nagasaka T, Nomoto S, Sugimoto H and Nakao A **Neuroendocrine-like differentiation in patients with pancreatic carcinoma.** *Cancer* 2000, **89**:2230-2236
 47. Guengerich FP **Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species.** *Chem Biol Interact* 1997, **106**:161-82
 48. Hasler JA **Pharmacogenetics of cytochromes P450.** *Mol Aspects Med* 1999, **20**:12-24
 49. Cubilla AL and Fitzgerald PJ **Morphological lesions associated with human primary invasive nonendocrine pancreas cancer.** *Cancer Res* 1976, **36**:2690-2698
 50. Kozuka S, Sassa R, Taki T, Masamoto K, Nagasawa S, Saga S, Hasegawa K and Takeuchi M **Relation of pancreatic duct hyperplasia to carcinoma.** *Cancer* 1979, **43**:1418-1428
 51. Furukawa T, Chiba R, Kobari M, Matsuno S, Nagura H and Takahashi T **Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen.** *Arch Pathol Lab Med* 1994, **118**:227-234
 52. Brockie E, Anand A and Albores-Saavedra J **Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma.** *Ann Diagn Pathol* 1998, **2**:286-292
 53. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB and Hruban RH **Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas.** *Am J Surg Pathol* 1998, **22**:163-169
 54. Hruban RH, Goggins M, Parsons J and Kern SE **Progression model for pancreatic cancer.** *Clin Cancer Res* 2000, **6**:2969-2972
 55. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E and Tempero MA **A white paper: the product of a pancreas cancer think tank.** *Cancer Res* 2001, **61**:4923-4932
 56. Egami H, Takiyama Y and Pour PM **Induction of multifocal pancreatic cancer after inoculation of hamster pancreatic cancer cell into a defined area of homologous pancreas.** *Cancer Lett* 1990, **50**:53-56
 57. Kloppel G and Heitz PU **Pancreatic, non-endocrine tumors.** In: *Pancreatic Pathology* (Edited by: Kloepfel G, Heitz PU) Churchill Livingstone 1984, 89
 58. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H and Shirai T **Genetic progression and divergence in pancreatic carcinoma.** *Am J Pathol* 2000, **156**:2123-2133
 59. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL and Bos JL **K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.** *Am J Pathol* 1993, **143**:545-54
 60. Day JD, DiGiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN, Kern SE and Hruban RH **Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms.** *Hum Pathol* 1996, **27**:119-24
 61. Standop J and Pour PM **A stronger and consistent expression of ErbB2 growth factor receptor in pancreatic islets and neuroendocrine cells compared to pancreatic cancer.** *Neuroendocrinology*
 62. Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE and Hruban RH **Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression.** *Cancer Res* 1998, **58**:4740-4744
 63. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ and Kern SE **Tumor-suppressive pathways in pancreatic carcinoma.** *Cancer Res* 1997, **57**:1731-174
 64. Moskaluk CA, Hruban RH and Kern SE **p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.** *Cancer Res* 1997, **57**:2140-2143
 65. Luetgtes J, Diederich A, MAOMenke H, Vogel I, Kremer B and Kloepfel G **Ductal lesions in patients with chronic pancreatitis show k-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53.** *Cancer* 2000, **88**:2495-2504
 66. Goggins M, Hruban RH and Kern SE **BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.** *Am J Pathol* 2000, **156**:1767-1771
 67. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth M, Buechler MW, Aubert JP and Batra SK **Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance.** *Clin Cancer Res* 2001, **7**:4033-4040
 68. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, Wilentz RE, Hruban RH and Argani P **MUC4 Expression increases progressively in pancreatic intraepithelial neoplasia (PanIN)** *Am J Clin Pathol* 2002, **117**:791-796
 69. Poulson R, Alison MR, Forbes SJ and Wriugh NA **Adult stem cell plasticity.** *J Pathol* 2002, **197**:441-456
 70. Feyrter F **Ueber die peripheren endokrinen (parakrinen) Druesen des Menschen.** *Wien-Duesseldorf: Wilhelm Maudrich*; 1953,
 71. Bonner-Weir S and Sharma A **Pancreatic stem cells.** *J Pathol* 2002, **197**:519-526
 72. De Lisle RC and Logsdon CD **Pancreatic acinar cells in culture: expression of acinar and ductal antigens in growth-related manner.** *Eur J Cell Biol* 1990, **51**:64-75
 73. Hall PA and Lemoine NR **Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas.** *J Pathol* 1992, **166**:97-103

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

